.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,407,914

« Back to Dashboard

Claims for Patent: 5,407,914

Title: Pulmonary surfactant protein and related polypeptides
Abstract:The present invention discloses useful peptides and synthetic pulmonary surfactants, as well as methods of making and using same. In a preferred embodiment, a synthetic pulmonary surfactant comprises one or more pharmaceutically acceptable phospholipids admixed with a polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions. In other embodiments, a surfactant peptide has an amino acid residue sequence selected from the group consisting of KLLLLKLLLLKLLLLKLLLLK, KLLLLLLLLKLLLLLLLLKLL, and KKLLLLLLLKKLLLLLLLKKL.
Inventor(s): Cochrane; Charles G. (La Jolla, CA), Revak; Susan D. (San Diego, CA)
Assignee: The Scripps Research Institute (La Jolla, CA)
Application Number:08/060,833
Patent Claims: 1. A synthetic pulmonary surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula (Z.sub.a U.sub.b).sub.c Z.sub.d, wherein:

Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K;

U is a hydrophobic amino acid residue independently selected from the group consisting of L and C;

a is 1 or 2;

b has an average value of about 3 to about 8;

c is 1 to 10; and

d is 0 to 2;

said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.

2. The synthetic pulmonary surfactant of claim 1, said polypeptide having an amino acid residue sequence represented by the formula:

3. The synthetic pulmonary surfactant of claim 1, said polypeptide having an amino acid residue sequence represented by the formula:

4. The synthetic pulmonary surfactant of claim 1, said polypeptide having an amino acid residue sequence represented by the formula:

5. A synthetic pulmonary surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide having an amino acid residue sequence represented by the formula:

said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.

6. A polypeptide having an amino acid residue sequence selected from the group consisting of:

7. A polypeptide according to claim 6, wherein said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forms a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.

8. A method of treating respiratory distress syndrome comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant, said surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide having alternating hydrophobic and hydrophilic amino acid residue regions, represented by the formula (Z.sub.a U.sub.b).sub.c Z.sub.d, wherein:

Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K;

U is a hydrophobic amino acid residue independently selected from the group consisting of L and C;

a is 1 or 2;

b has an average value of about 3 to about 8;

c is 1 to 10; and

d is 0 to 2;

said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.

9. The method of claim 8, wherein said polypeptide has an amino acid residue sequence represented by the formula:

10. The method of claim 8, wherein said polypeptide has an amino acid residue sequence represented by the formula:

11. The method of claim 8, wherein said polypeptide has an amino acid residue sequence represented by the formula:

12. A method of treating respiratory distress syndrome comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant, said surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide having an amino acid residue sequence represented by the formula:

said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc